As we speculated, the degradation of the silica shell inside lysosomes (with the subsequent release of intact protein cargoes) may represent an interesting opportunity for the treatment of LSDs: the delivery of the active galactoceribrosidase (GALC) enzyme to lysosomes as an enzyme replacement therapy (ERT) represents, for instance, the preferred choice of treatment for the rare Krabbe disease [34]. The gene discussed is GALC; the disease is Krabbe disease.